MESO

Mesoblast Limited

15.50 USD

Last updated Sep 12, 01:28 UTC

Yesterday HIGH

$15.8

Yesterday LOW

$15.46

52w HIGH

$21.49

52w LOW

$13.05

EPS

-0.04

PE

-352.27

Next Earnings

Feb 25, 2027

Overview News Unusual Options Flow Government Trades Fundamentals

Mesoblast Limited stock is down -7.63% since 30 days ago. The next earnings date is Feb 25, 2027. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 45.45% of the previous 10 September’s closed higher than August. In the last 10 Unusual Options Trades, there were 10 CALLs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time	Expiration Date	Strike Price	Trade Type	Size	Open Interest

10 Sep 13:45	15 Jan, 2027	18.00	CALL	190	787
10 Sep 13:46	15 Jan, 2027	18.00	CALL	190	787
11 Sep 14:22	21 Jan, 2028	17.00	CALL	50	2758
11 Sep 14:23	21 Jan, 2028	30.00	CALL	100	1378
11 Sep 14:24	21 Jan, 2028	30.00	CALL	100	1378
11 Sep 14:30	21 Jan, 2028	17.00	CALL	50	2758
11 Sep 14:34	21 Jan, 2028	30.00	CALL	121	1378
11 Sep 14:43	21 Jan, 2028	30.00	CALL	100	1378
11 Sep 15:07	21 Jan, 2028	25.00	CALL	100	3888
11 Sep 15:12	21 Jan, 2028	17.00	CALL	60	2758

Advanced Data Unlock

Benzinga Newsdesk

Thu Jun 25, 2026

Mesoblast shares are trading lower. The company drew down $50 million from its five-year facility.
Benzinga Newsdesk

Thu Jun 25, 2026

Reported Earlier, Mesoblast Strengthens Balance Sheet With $50M Drawdown From Five-Year Non-Dilutive Facility, Retiring Higher-Cost Short-Term Debt Obligations
Benzinga Insights

Mon Jun 1, 2026

10 Health Care Stocks With Whale Alerts In Today's Session
Tim Melvin

Thu May 7, 2026

Alpha Buying: Insider Conviction in High-Risk Biotech
Benzinga Newsdesk

Thu Apr 30, 2026

Reported Earlier, Mesoblast Reports $30.3M Ryoncil Net Revenues In Q3, $122M Cash On Hand And Achieved Patient Recruitment Target In Phase 3 Back Pain Trial
Benzinga Newsdesk

Wed Apr 29, 2026

Reported Earlier, Mesoblast Reaches Patient Recruitment Target In Phase 3 Trial For Non-Opioid Chronic Low Back Pain Therapy
Benzinga Newsdesk

Wed Apr 15, 2026

Reported Earlier, Mesoblast Acquires Exclusive Worldwide License To Mayo Clinic-Developed CAR Technology Platform To Boost Effectiveness Of MSC Products For Inflammatory Diseases
Benzinga Newsdesk

Fri Apr 10, 2026

Mesoblast Receives Investigational New Drug Clearance From FDA For Registrational Clinical Trial For Duchenne Muscular Dystrophy Treatment Ryoncil
Benzinga Newsdesk

Wed Apr 8, 2026

Reported Earlier, Mesoblast's FDA-Approved Ryoncil Gets IND Clearance For Registrational DMD Trial, To Randomize 76 Patients Aged 5-9 Years Across 7 Infusions Over 9 Months

Partnering with Parent Project Muscular Dystrophy to ensure timely access to the trial for eligible patients~15,000 children are living with DMD in the U.S.
Avi Kapoor

Tue Apr 7, 2026

Mach Natural Resources, Mesoblast And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

U.S. stock futures down, Nasdaq 100 falls over 100 points. Mach Natural Resources LP (MNR) shares dip 7.6% in pre-market trading.

Piper Sandler

Thu Aug 27, 19:24

buy

confirm

Advanced Data Unlock

NTLA $11.73 USD

ALOY ALOY $8.42 USD

JMKE $21.65 USD

GS $1,029.08 USD

LEU $152.14 USD